Marinus Pharmaceuticals (MRNS) News Today $1.43 +0.01 (+0.70%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 12:10 PM | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusJuly 26 at 11:28 AM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSJuly 26 at 5:45 AM | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 5, 2024 in Marinus Pharmaceuticals, Inc. Lawsuit - MRNSJuly 25 at 9:55 PM | markets.businessinsider.comMarinus Pharmaceuticals (MRNS) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud LawsuitJuly 25 at 6:05 PM | globenewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNSJuly 25 at 12:33 PM | globenewswire.comClass Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for Investors – Contact Levi & KorsinskyJuly 25 at 9:55 AM | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusJuly 25 at 5:45 AM | prnewswire.comThe Gross Law Firm Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNSJuly 25 at 4:34 AM | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Crosses Below Two Hundred Day Moving Average of $5.34July 25 at 4:32 AM | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Shares Cross Below 200 Day Moving Average of $5.34Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Pass Below Two Hundred Day Moving Average of $5.34July 25 at 2:02 AM | insidermonkey.comMarinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts?July 24 at 1:44 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSJuly 24 at 12:46 PM | markets.businessinsider.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusJuly 24 at 11:15 AM | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law FirmJuly 23 at 4:40 PM | msn.comMarinus Pharmaceuticals Gains Approval for Seizure Drug in ChinaJuly 23 at 11:00 AM | globenewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmJuly 22, 2024 | globenewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)July 22, 2024 | globenewswire.comShareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact The Gross Law Firm about pending Class Action - MRNSJuly 22, 2024 | prnewswire.comShareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNSJuly 20, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSJuly 20, 2024 | globenewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNSJuly 20, 2024 | americanbankingnews.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $13.79 Consensus PT from AnalystsJuly 19, 2024 | stockhouse.comMarinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency DisorderJuly 19, 2024 | markets.businessinsider.comMarinus Pharma Says Ganaxolone To Treat Seizures Associated With CDD Approved In ChinaJuly 19, 2024 | prnewswire.comFaruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on August 5, 2024 in Marinus LawsuitJuly 18, 2024 | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by The Rosen Law FirmJuly 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSJuly 18, 2024 | prnewswire.comShareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNSJuly 17, 2024 | globenewswire.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNSJuly 17, 2024 | globenewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmJuly 17, 2024 | prnewswire.comMarinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNSJuly 17, 2024 | marketbeat.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Rating of "Moderate Buy" from AnalystsMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have issuedJuly 16, 2024 | globenewswire.comLevi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MRNSJuly 16, 2024 | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law FirmJuly 16, 2024 | globenewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)July 16, 2024 | marketbeat.comMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Price Crosses Above 50-Day Moving Average of $1.37Marinus Pharmaceuticals (NASDAQ:MRNS) Share Price Passes Above 50 Day Moving Average of $1.37July 15, 2024 | globenewswire.comThe Gross Law Firm Reminds Marinus Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 – MRNSJuly 15, 2024 | prnewswire.comLost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyJuly 13, 2024 | globenewswire.comROSEN, A LEADING AND RANKED FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNSJuly 12, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSJuly 12, 2024 | prnewswire.comShareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact The Gross Law Firm about pending Class Action - MRNSJuly 11, 2024 | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by The Rosen Law FirmJuly 11, 2024 | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud LawsuitJuly 10, 2024 | globenewswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNSJuly 10, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSJuly 10, 2024 | globenewswire.comInvestors who lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact Levi & Korsinsky about pending Class Action - MRNSJuly 10, 2024 | globenewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmJuly 9, 2024 | prnewswire.comClass Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) - August 5, 2024 Deadline to Join - Contact Levi & KorsinskyJuly 9, 2024 | globenewswire.comMarinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 – MRNSJuly 9, 2024 | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Rare signal predicts 50% market drop - before election (Ad)The market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors. Take these 4 steps to protect your retirement here. MRNS Media Mentions By Week MRNS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRNS News Sentiment▼0.140.62▲Average Medical News Sentiment MRNS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRNS Articles This Week▼264▲MRNS Articles Average Week Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RAPT Therapeutics News Today Aurora Cannabis News Today Sutro Biopharma News Today Enanta Pharmaceuticals News Today Adaptimmune Therapeutics News Today Cartesian Therapeutics News Today ADC Therapeutics News Today Akebia Therapeutics News Today CorMedix News Today Zevra Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRNS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
